{
    "nct_id": "NCT05371834",
    "official_title": "Pivotal Study to Assess the Clinical Efficacy and Safety of Microwave Treatment in Warts",
    "inclusion_criteria": "1. Provision of signed and dated informed consent form;\n2. Stated willingness to comply with all study procedures and availability for the duration of the study;\n3. Age 18-64 years inclusive;\n4. A minimum of one clinically significant common wart (usually found on hands, knees and elbows), or one plantar wart. Note: the warts for treatment cannot be a mixture of common and plantar warts;\n5. Subject's common warts must measure between 3mm-10mm or for plantar warts, measure between 3mm-20mm, inclusive;\n6. If currently receiving treatment for common or plantar warts, agree to stop their current medication for at least 28 days prior to the start of study treatment;\n7. Agrees to refrain from using any other wart removal products or treatments during the study period;\n8. Agrees to not take any non-steroidal anti-inflammatory drugs (NSAIDs) or antihistamines within a 12-hour period prior to and after randomized treatment;\n9. Able to perform study assessments.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 64 Years",
    "exclusion_criteria": "1. Pregnancy or breast feeding;\n2. Mosaic warts for treatment;\n3. Warts (common or plantar) that have been reported by the subject as present for more than 5 years (relates to any wart present and which may not necessarily be treated in this study);\n4. Warts for treatment on areas of thin or sensitive skin as determined by the Investigator, e.g., face, neck, armpits, breasts, buttocks or genitals;\n5. Areas for treatment where the skin is irritated, reddened or showing any sign of inflammation (e.g. itching and swelling);\n6. Warts for treatment with hair growth, birthmarks, dark moles, pigmented skin or any other unusual skin condition;\n7. History of infection in designated treatment area within 90 days prior to first treatment;\n8. Implantable Cardioverter Defibrillator (ICD), pacemaker or other implantable electronic devices;\n9. Metal implants at site of treatment (within foot or ankle);\n10. Known allergy or intolerance to microwave therapy and cryotherapy;\n11. Unstable co-morbidities (cardiovascular disease, active malignancy, inflammatory arthritis);\n12. Participating in another interventional study or have done so within the last 30-days;\n13. Anticipated relocation or extensive travel outside of the local study area preventing compliance with study procedures;\n14. Circulatory conditions affecting the acral areas - peripheral vascular disease, peripheral ischemia, vasculitis, Raynaud's, or related conditions;\n15. Peripheral neuropathy;\n16. Subject with known immunosuppression disorders through illness or medication (for example - corticosteroids, biologic agents, methotrexate, ciclosporin);\n17. Subject with autoimmune disease;\n18. Diabetes (Type I or II);\n19. History of vascular interventions to the legs, deemed as an unacceptable risk by the Investigator;\n20. Prior dissection of axillary lymph nodes (for treated hand) or inguinal lymph nodes (for treated feet);\n21. Dependent lymphedema;\n22. Congestive heart failure;\n23. History of repeated cellulitis (2 or more episodes);\n24. History of deep venous thrombosis;\n25. Subject currently receiving prescribed blood thinning medication;\n26. Subject who has ever had any topical metallic treatment (e.g, aluminum chloride, silver nitrate) within the past year.",
    "miscellaneous_criteria": ""
}